News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG Highlights Operational Achievements and Reports Financial Results for First Six Months 2019

PDF Berlin (Germany) and San Diego, CA (U.S.A.), August 7, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) today announced the operational achievements plus financial results for the second quarter and the first half of 2019. Operational highlights – In January 2019, the Company announced positive results from a microsimulation model for the […]

Read more

Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon®, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates

PDF Berlin, 24 July 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology, today reported new study results suggesting that Epi proColon®, a CRC screening test approved for patients who are unwilling or unable to be screened by […]

Read more

Epigenomics AG Receives MedTech Outlook‘s 2019 Top 10 In-Vitro Diagnostics Award

PDF – Company recognized for its leadership in advancing blood-based tests to diagnose cancer Berlin (Germany) and San Diego, CA (U.S.A.), July 11, 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced today that it was selected by MedTech Outlook to receive the 2019 Top 10 In-Vitro Diagnostics Award. Conducted annually, the award […]

Read more

New Clinical Data Support the Utility of Epi proColon® Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome

PDF Minimally-invasive blood test could complement colonoscopy in high-risk LS patients who are non-compliant with colonoscopy screening recommendations or may develop precancerous lesions in the interval between colonoscopies Berlin (Germany), June 17, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary […]

Read more

Epigenomics AG to Participate in Raymond James Life Sciences and MedTech Conference in June

PDF Berlin (Germany) and San Diego, CA (U.S.A.), June 4, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced that company management will be presenting at the Raymond James Life Sciences and MedTech Conference in New York on Tuesday, June 18, 2019, at 1:50 pm (EDT) / 7:50 pm (CET) and invites […]

Read more

New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon® Blood Test

PDF Data Presented at DDW 2019 Show 93.6% Acceptance Rate Among Patients Unwilling or Unable to Complete Other CRC Screening Tests Berlin (Germany) and San Diego, CA (U.S.A.), May 20, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation […]

Read more